Open Orphan Share Discussion Threads

[pogue] 19/11/2020 09:36

Pierre not just the staff at ORPH you get but the challenge study models which take time and money to develop, UK gov paying £20 million for CV19 one, however time is the biggest issue I suggest right now as the contracts are out there to be picked up and ORPH are picking numbers on how much they want to charge as there is no real challenger. Edit £10 million for model, £40 million less 3 x £10 million for the studies typing faster than I think as usual.

[pierre oreilly] 19/11/2020 09:34

p, o/t Geneva is a fantastic place, worked there for 4 years. The pay compensates for the high cost of living, and the benefit is when you go anywhere else, it seems really cheap, as you say, even central london. The uk and french speaking switzerland are the only 2 places I'd live, having worked all over the shop. .... One area i disagree with c is giving shares to staff. He's said if they want shares, they have to buy them, just like he and his other directors do. He won't get orph to buy shares to give to the staff as bonuss. I wish he would. He cuts orph's costs to the min, but buying say100k worth of shares in the market to give to staff would benefit shareholders too . I understand why he doesn't just print more paper to give away - and i fully agree with him on that one.

[malcolmmm] 19/11/2020 09:27

I was on the computer side so never got those unfortunately but it is an incentive to remain loyal.Saying that FX dealers were poached from time to time

[pogue] 19/11/2020 09:26

Pierre didn't work there but visit a friend in Geneva who is working there for weekends on occasion. Been to the restaurants etc and shocked at the price of very average dishes and he tells me about the day to day costs of living and working there as I have had calls about going there to work in the past so looked at the cost benefits. Best option is commuting from France if you can get it set up.

[judijudi] 19/11/2020 09:21

Malc, The less said about banking bonuses the better 🤣😂

[malcolmmm] 19/11/2020 09:19

We received bonus shares yearly if the bank did well we were rewarded

[pogue] 19/11/2020 09:18

Judijudi if you notice in the presentations he is always playing down take overs and burnishing the staff egos however in the end the fact that ORPH will be leading the charge in the sector to me will make them stay. Regards more money just think about how many £millions one challenge study makes and therefore how much money is at CF's disposal to pay to a small Ltd company providing services and whose directors can then take as divis. A large multinational will have pay scales and procedures to follow on payments to employees which they would find hard to circumvent without causing riots among the existing staff.

[inaminute] 19/11/2020 09:14

Who is to say they haven't got shares in the company? I worked for a company once where it was common knowledge internally that the objective was to sell when a buyer came along at the right price. I just stacked up on shares and went there richer.

[pierre oreilly] 19/11/2020 09:14

m5, 1416 - going back i agree is often not the best thing to do. But the chimagents couple went back to hvivo seemingly successfully.

[malcolmmm] 19/11/2020 09:11

I also would have thought that the staff would be givern shares in the company as an added incentive. When I worked for Chase they did that

[pierre oreilly] 19/11/2020 09:11

o/t P, not more in common. Where did you work in Switzerland? What sgs does depends on what they want, if anything. If they want chimagents back, they could easily offer them a higher rate, and even pay any penalties to hvivo if they break a contract. If sgs want the challenge study business (which to my mind is the only feasible requirement - you can't build a business just relying on a couple of people, as they've found out) then i'd guess they'd takeout the whole of orph. the other bits could also fit in with their conglomerate status. Although pure speculation, i'd estimate there's a real chance of sgs wanting orph - it makes a lot of business sense to sgs imv. (I'm not saying 'sgs is about to takeover orph').

[judijudi] 19/11/2020 09:11

Orph has now got to be worth nearer the £1 mark Surely Although in the real world whole PLC company sales are a rare beast. Partial PLC company sales less so

[judijudi] 19/11/2020 09:09

Pogue So would you be happy as a newly poached (from SGS) staff member to think that your CEO is talking about possibly selling to the company you have just left to join Orph? I think it must be unsettling for most of the staff to be told by their CEO that the company is up for sale bwtfdik

[malcolmmm] 19/11/2020 09:09

I am thinking that once ORPH get the go ahead from the ethics committee that they will be bid for by a big phama or two.

[m5] 19/11/2020 09:07

pogu, I would agree with that. Whilst money is an important factor for us all, and I am sure it will have been worth their while, people leave for other reasons and going back does not always turn out well. I am sure CF will have worked his charms on them l and I can imagine that whilst expecting a lot, he will be a decent and straight forward guy to work for and with.

[pogue] 19/11/2020 08:58

Warranty I am guessing here but I suggest CF brought back the old team on two points, one they were going to be paid as contractors rather than staff, the setting up of the little company they are all in suggests that, hence they got a large pay boost. Secondly I suspect the carrot of working at the lead company in a booming sector appeals to their egos as they will be on committees etc and regarded as the world leaders in their field this is important to scientific types in my experience. Edit also from experience Switzerland is rock hard expensive to live in it makes London look cheap.

[troutisout] 19/11/2020 08:53

hxxps://asm.org/Articles/2019/August/A-Universal-Influenza-Vaccine-How-Close-Are-We

[warranty] 19/11/2020 08:50

Is there anything to stop SGS from poaching the people and others back from Orph/Hvivo? They must have deeper pockets than Orph and it would be cheaper than buying the company with bits they don’t really want. Do we have the main people tied to contracts that can’t be broken?

[pogue] 19/11/2020 08:48

To me the RNS read as we are setting the standard others must follow and our procedures for manufacturing will be used as the starting point for the standards I expect, you need a base template to start with to work on. I have written standards in engineering so am familiar with the process. Clearly ours will then be the basis of the standard since we are in charge of setting it up and will have most influence on the committee. The mere fact that a standard for manufacturing agents outside of the labs they are currently made in points to a dramatic expansion in the industry outside its current small base again verifying CFs optimism on a decade of virus challenge studies. In the last presentation CF was a bit more cagey on when he plans to sell ORPH that can be read two ways one, he is looking at a longer time frame, two, he is well on the way to doing it and is keeping stum. Who knows which but worth probing him tonight on how he is feeling if a bidder appeared since we seem to be at the beginning of a sectorial boom which we ride or sell into based on large future profits.

[readdin] 19/11/2020 08:42

I think the welcome news is worth more than 1/2p

[m5] 19/11/2020 08:35

Cheers guys, thanks for posting it up.

[owenski] 19/11/2020 08:29

m5, cheers, I've found it now on company website.

[pierre oreilly] 19/11/2020 08:29

Since the biondvax uni flu vaccine failed phase 3, afaiia, there are currently no phase 3 uni flu trials on going. So imutex is the most advanced having passed stage 2 and in addition 3 challenge studies, as c pointed out.. No idea whether there are other candidates which have passed phase 2. Whatever, that's why imutex has a high value, some big pharma interested in a uni flu vaccine could take the risk and fund phase 3, something orph won't do. What's likely imv (warning, speculation) is that c will try to reverse Imutex into the boindvax remnants and therefore acquire a nas quote and raise cash on the nas during the reversal. If that happens - and it's exactly where C's expertise lies - then we'll all get a Divi in the form of new biondvax shares. ........... The Rns is great for stating to the world that hvivo is the accepted and respected world leader in challenge trials.

[owenski] 19/11/2020 08:28

if anyone want to register for tonight's presentation on Pro-active - Https://www.openorphan.com/investors/key-dates-calender